apxt505
United Kingdom
Edited
Market Report 16th February In the mirror world of the financial markets bad news - weak January retail sales in the US – is viewed as good news (i.e. the consumer is weakened by rising credit costs/threat of unemployment). This conflicts with all the other evidence that the US economy and consumer are in great shape, but the 'conventional narrative' says that this puts pressure on the Fed to cut interest rates (See! You have gone too far!). It is now pretty clear to most people that cuts have been pushed back to the second half of the year. In the meantime the animal spirits in the market are lively almost as if everyone is fed up with the Fed psychodrama and is getting on with making money. Hence the portfolio specific news. $SMCI (Super Micro Computer, Inc) of course, as always, as this stock cannot find a top. In other portfolio specific news Recursion Pharmaceuticals $RXRX (Recursion Pharmaceuticals Inc) is up 36.78% on the week based on NVIDIA's investment in the company's AI driven research; $IQV (IQVIA Holdings Inc.) is up 13.29% this week based on earnings; Today the spotlight turns to pharma investment $BPMC (Blueprint Medicines Corp) Blueprint Medicine up +14% in pre-market (according to Yahoo finance) and $TTD (Trade Desk Inc A) Trade Desk also up +19% in pre-market (according to Yahoo finance) at 9:46 GMT. The rise in Blueprint's price is attributable to specific comments in their earnings call re their new treatment Ayvakit. The Trade Desk operates a self-service cloud platform for digital advertising campaigns. None of the above is investment advice and you must do your own research before taking any investment decision. I am +2.07% for the year to date in 2024; +20.84% for the calendar year 2023. check it out www.etoro.com/people/apxt505/portfolio